Brief: Aardvark Therapeutics Announces FDA Alignment On Protocol Amendment Expanding Phase 3 Hero Trial Population For Prader-Willi Syndrome
08/10/2025 13:16
Oct 8 (Reuters) - Aardvark Therapeutics Inc AARD.O: AARDVARK THERAPEUTICS ANNOUNCES FDA ALIGNMENT ON PROTOCOL AMENDMENT EXPANDING PHASE 3 HERO TRIAL POPULATION FOR PRADER-WILLI SYNDROME AARDVARK THERAPEUTICS ANNOUNCES FDA ALIGNMENT ON PROTOCOL AMENDMENT EXPANDING PHASE 3 HERO TRIAL POPULATION FOR PRADER-WILLI SYNDROME AARDVARK THERAPEUTICS INC - TRIAL ELIGIBILITY AGE CHANGED FROM 13 TO 10 YEARS AARDVARK THERAPEUTICS INC - TOPLINE DATA READOUT FOR TRIAL EXPECTED IN Q3 2026 Source text: ID:nGNX2wRJCK Further company coverage: AARD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aardvark Therapeutics
See all newsBrief: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., Mba, To Its Board Of Directors
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark